

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| | | |
|------------------------|---------------|------------|
| Application Number | | 10575592 |
| Filing Date | | 2006-04-12 |
| First Named Inventor | Kettle | |
| Art Unit | 1624 | |
| Examiner Name | Mark L. Berch | |
| Attorney Docket Number | 101250-1P US | |

| U.S.PATENTS | | | | | | Remove |
|-------------------|---------|---------------|------------------------|------------|---|--|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | 3135753 | | 1964-06-02 | Hitchings et al. | |
| | 2 | 4820709 | | 1989-04-11 | Hofer | |
| | 3 | 5173491 | | 1992-12-22 | Kamoun et al. | |
| | 4 | 5489598 | | 1996-02-06 | Connor et al. | |
| | 5 | 5716967 | | 1998-02-10 | Kleinman | |
| | 6 | 5756511 | | 1998-05-26 | West et al. | |
| | 7 | 5976823 | | 1999-11-02 | Wu | |
| | 8 | 6025361 | | 2000-02-15 | Cavalla et al. | |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|---------------|
| Application Number | 10575592 |
| Filing Date | 2006-04-12 |
| First Named Inventor | Kettle |
| Art Unit | 1624 |
| Examiner Name | Mark L. Berch |
| Attorney Docket Number | 101250-1P US |

| | | | | | |
|----|---------|--|------------|-------------------|--|
| 9 | 6046019 | | 2000-04-04 | Goumeniouk et al. | |
| 10 | 6066641 | | 2000-05-23 | Cavalla et al. | |
| 11 | 6294541 | | 2001-09-25 | Cavalla et al. | |
| 12 | 6319928 | | 2001-11-20 | Chasin et al. | |
| 13 | 7108997 | | 2006-09-19 | Kettle | |

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|--------------------|------------------------|------------------|---|--|
| | 1 | 20040022871 | | 2004-02-05 | Mainnemare | |
| | 2 | 20040029871 | | 2004-02-12 | Thong et al. | |
| | 3 | 20050070558 | | 2005-03-31 | Vidal Juan et al. | |
| | 4 | 20050234036 | | 2005-10-20 | Hanson et al. | |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|---------------|------------|
| Application Number | | 10575592 |
| Filing Date | | 2006-04-12 |
| First Named Inventor | Kettle | |
| Art Unit | 1624 | |
| Examiner Name | Mark L. Berch | |
| Attorney Docket Number | 101250-1P US | |

| | | | | | |
|---|-------------|--|------------|-----------------|--|
| 5 | 20070093483 | | 2007-04-26 | Svensson et al. | |
|---|-------------|--|------------|-----------------|--|

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² i | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
|-------------------|---------|--------------------------------------|-----------------------------|------------------------|------------------|---|--|-------------------------------------|
| | 1 | 1013676 | CN | | 1991-08-28 | Euroceltique S.A. | | <input checked="" type="checkbox"/> |
| | 2 | 0010531 | EP | | 1982-06-02 | Aktiebolaget Draco Fack | | <input type="checkbox"/> |
| | 3 | 0359505 | EP | | 1990-03-21 | Smithkline Beecham Corporation | | <input type="checkbox"/> |
| | 4 | 0430300 | EP | | 1991-06-05 | Takeda Chemical Industries, Ltd | | <input type="checkbox"/> |
| | 5 | 0452926 | EP | | 1996-03-13 | Merrell Dow Pharmaceuticals Inc. | | <input type="checkbox"/> |
| | 6 | 01016407 | EP | | 2006-05-10 | Kyowa Hakko Kogyo Co., Ltd | | <input type="checkbox"/> |
| | 7 | 02160235 | JP | | 1990-06-20 | Konica Corp | | <input type="checkbox"/> |
| | 8 | 8906125 | WO | | 1989-07-13 | Smithkline Beckman Corporation | | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|---------------|------------|
| Application Number | | 10575592 |
| Filing Date | | 2006-04-12 |
| First Named Inventor | Kettle | |
| Art Unit | 1624 | |
| Examiner Name | Mark L. Berch | |
| Attorney Docket Number | 101250-1P US | |

| | | | | | | | |
|----|----------|----|--|------------|--------------------------------|--|--------------------------|
| 9 | 9500516 | WO | | 1995-01-05 | Euro-Celtique S.A. | | <input type="checkbox"/> |
| 10 | 9914204 | WO | | 1999-03-25 | G.D. Searle & Co. | | <input type="checkbox"/> |
| 11 | 9917773 | WO | | 1999-04-15 | Smithkline Beecham Corporation | | <input type="checkbox"/> |
| 12 | 9936073 | WO | | 1999-07-22 | Cell Therapeutics Inc. | | <input type="checkbox"/> |
| 13 | 9940091 | WO | | 1999-08-12 | Amgen Inc. | | <input type="checkbox"/> |
| 14 | 0051598 | WO | | 2000-09-08 | Smithkline Beecham Corporation | | <input type="checkbox"/> |
| 15 | 0059449 | WO | | 2000-10-12 | Euro-Celtique S.A. | | <input type="checkbox"/> |
| 16 | 0185146 | WO | | 2001-11-15 | AstraZeneca AB | | <input type="checkbox"/> |
| 17 | 02006272 | WO | | 2002-01-24 | Sanofi-Synthelabo | | <input type="checkbox"/> |
| 18 | 02066447 | WO | | 2002-08-29 | Ono Pharmaceutical Co., Ltd | | <input type="checkbox"/> |
| 19 | 02090575 | WO | | 2002-11-14 | AstraZeneca AB | | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|---------------|------------|
| Application Number | | 10575592 |
| Filing Date | | 2006-04-12 |
| First Named Inventor | Kettle | |
| Art Unit | 1624 | |
| Examiner Name | Mark L. Berch | |
| Attorney Docket Number | 101250-1P US | |

| | | | | | | | | |
|--|----|------------|----|--|------------|--------------------------------|--|--------------------------|
| | 20 | 03000694 | WO | | 2003-01-03 | Almirall Prodesfarma S. A. | | <input type="checkbox"/> |
| | 21 | 03082873 | WO | | 2003-10-09 | Almirall Prodesfarma S. A. | | <input type="checkbox"/> |
| | 22 | 2004096781 | WO | | 2004-11-11 | AstraZeneca AB | | <input type="checkbox"/> |
| | 23 | 2005042534 | WO | | 2005-05-12 | CV Therapeutics Inc. | | <input type="checkbox"/> |
| | 24 | 2005077950 | WO | | 2005-08-25 | Smithkline Beecham Corporation | | <input type="checkbox"/> |
| | 25 | 2006045564 | WO | | 2006-05-04 | Smithkline Beecham Corporation | | <input type="checkbox"/> |
| | 26 | 2006046910 | WO | | 2006-05-04 | AstraZeneca AB | | <input type="checkbox"/> |
| | 27 | 2006062465 | WO | | 2006-06-15 | AstraZeneca AB | | <input type="checkbox"/> |
| | 28 | 2007142576 | WO | | 2007-12-13 | AstraZeneca AB | | <input type="checkbox"/> |

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS

Remove

| | | | |
|--------------------|---------|---|----------------|
| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
|--------------------|---------|---|----------------|

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|---------------|--------------|
| Application Number | | 10575592 |
| Filing Date | | 2006-04-12 |
| First Named Inventor | Kettle | |
| Art Unit | | 1624 |
| Examiner Name | Mark L. Berch | |
| Attorney Docket Number | | 101250-1P US |

| | | |
|----|---|--------------------------|
| 1 | AARON, S D et al., "Granulocyte Inflammatory Markers and Airway Infection during Acute Exacerbation of Chronic Obstructive Pulmonary Disease," Am J Respir Crit Care Med., 2001, pgs. 349-355, vol. 163 | <input type="checkbox"/> |
| 2 | AKBIYIK et al., "In vitro and in vivo inhibition of myeloperoxidase with 5-fluorouracil," Eur. J. Clin. Pharmacol., 2001, Vol. 57, pgs. 631-636 | <input type="checkbox"/> |
| 3 | ARMITAGE et al., "Structure-Activity Relationships in a Series of 6-Thioxanthines with Bronchodilator and Coronary Dilator Properties," British Journal of Pharmacology and Chemotherapy (1961), Vol. 17, pgs 196-207 | <input type="checkbox"/> |
| 4 | BERLOW et al., "The Effect of Dapsone in Steroid-Dependent Asthma," 1991, J. Allergy Clin. Immunol., 1991, Vol. 87 (3), pgs. 710-715 | <input type="checkbox"/> |
| 5 | BOZEMAN et al., "Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone," Biochemical Pharmacology, 1992, Vol. 44, No. 3, pgs. 553-563 | <input type="checkbox"/> |
| 6 | DALLEGRI et al., "Possible Modes of Action of Nimesulide in Controlling Neutrophilic Inflammation," Arzneimittel-Forschung/Drug Research, 1995, Vol. 45(II), No. 10, pgs. 1114-1117 | <input type="checkbox"/> |
| 7 | GARST et al., "Inhibition of Separated Forms of Phosphodiesterases from Pig Coronary Arteries by Uracils and by 7-Substituted Derivatives of 1-Methyl-3-isobutylxanthine," J. Med. Chem.; 1976; Vol. 19(4) pgs 499-503 | <input type="checkbox"/> |
| 8 | GRISHAM et al., "Assessment of Leukocyte involvement during Ischemia and Reperfusion of Intestine," Am. J. Physiol., 1986, Vol. 251, pgs. 729-743 | <input type="checkbox"/> |
| 9 | HOPE et al., "Large scale purification of myeloperoxidase from HL60 promyelocytic cells: characterization and comparison to human neutrophil myeloperoxidase," Protein Expression and Purification, 2000, Vol. 18, pgs. 269-276 | <input type="checkbox"/> |
| 10 | IMAI et al., "Studies on Nucleic Acid Antagonists. VII. Synthesis and Characterization of 1,4,6-Triazaindenes (5H-Pyrrolo(3,2-d)pyrimidines)" Chem. Pharm. Bull., 1964, Vol. 12, No. 9, pgs. 1030-1042 | <input type="checkbox"/> |
| 11 | JACOBSON et al., "1,3-Dialkylxanthine Derivatives Having High Potency as Antagonists at Human A2B Adenosine Receptors," Drug Development Research, 1999, Vol. 47, pgs 45-53 | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|---------------|
| Application Number | 10575592 |
| Filing Date | 2006-04-12 |
| First Named Inventor | Kettle |
| Art Unit | 1624 |
| Examiner Name | Mark L. Berch |
| Attorney Docket Number | 101250-1P US |

| | | |
|----|---|-------------------------------------|
| 12 | KETTLE et al., "Assays for the Chlorination Activity of Myeloperoxidase," Biophyl, 1992, Vol. 296, pgs. 502-513 | <input type="checkbox"/> |
| 13 | KETTLE et al., "Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs," Biochemical Pharmacology, 1991, Vol. 41, No. 10, pgs. 1485-1492 | <input type="checkbox"/> |
| 14 | KETTLE et al., "Superoxide is an Antagonist of Anti-Inflammatory Drugs that Inhibit Hypochlorous Acid Production by Myeloperoxidase," Biochemical Pharmacology, 1993, Vol. 45, No. 10, pgs. 2003-2010 | <input type="checkbox"/> |
| 15 | Khimicheskaya encyclopedia, ed. by Knunyants I.L., "Sovetskaya encyclopedia", 1990, V. 2, pg. 1083 | <input checked="" type="checkbox"/> |
| 16 | NOCKER et al., "Interleukin-8 in Airway Inflammation in Patients with Chronic Asthma and Chronic Obstructive Pulmonary Disease," Int. Arch Allergy Immunol., 1996, Vol. 109, pgs. 183-191 | <input type="checkbox"/> |
| 17 | OTTONELLO et al., "Sulphonamides as Anti-Inflammatory Agents: Old Drugs for New Therapeutic Strategies in Neutrophilic Inflammation," Clinical Science, 1995, Vol. 88, pgs. 331-336 | <input type="checkbox"/> |
| 18 | RAO et al., "Synthesis of 5,7-Disubstituted-4-Beta-D-ribofuranosylpyrazolo[4,3-d]-pyrimidines and 2,4-Disubstituted-1-Beta-D-ribofuranosylpyrrolo[3,2-d]-pyrimidines as Congeners of Uridine and Cytidine," J. Heterocyclic Chemistry, 1992, Vol. 29, pgs 343-354 | <input type="checkbox"/> |
| 19 | SUZUKI et al., "Assay method for myeloperoxidase in human polymorphonuclear leukocytes," Analytical Biochemistry, 1983, Vol. 132, pgs. 345-352 | <input type="checkbox"/> |
| 20 | VAN GALEN et al., "A Binding Site Model and Structure-Activity Relationships for the Rat A3 Adenosine Receptor," Molecular Pharmacology, 1994, Vol. 45, pgs 1101-1111 | <input type="checkbox"/> |
| 21 | WOO et al., "Inhibitors of Human Purine Nucleoside Phosphorylase. Synthesis and Biological Activities of 8-Amino-3-benzylhypoxanthine and Related Analogues," J. Med. Chem., 1992; Vol. 35, pgs 1451-1457 | <input type="checkbox"/> |
| 22 | WOOLDRIDGE et al., "The Synthesis of Some 6-Thioxanthines," J. Chem. Soc., 1962, pgs 1863-1868 | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|---------------|--------------|
| Application Number | | 10575592 |
| Filing Date | | 2006-04-12 |
| First Named Inventor | Kettle | |
| Art Unit | | 1624 |
| Examiner Name | Mark L. Berch | |
| Attorney Docket Number | | 101250-1P US |

| | | |
|----|---|--------------------------|
| 23 | STN printout for Registry No. 582-33-2: 3-Aminobenzoic acid ethyl ester | <input type="checkbox"/> |
| 24 | STN Intl, Registry No. 2487-40-3 | <input type="checkbox"/> |
| 25 | English abstract for JP 02160235 | <input type="checkbox"/> |
| 26 | English abstract for WO 2002006272 | <input type="checkbox"/> |
| 27 | Copy of non-final OA issued for 10/511537 on April 27, 2007, AstraZeneca Ref. 100647 | <input type="checkbox"/> |
| 28 | Copy of OA issued for 10/511537 on August 27, 2007, AstraZeneca Ref. 100647 | <input type="checkbox"/> |
| 29 | Copy of non-final OA issued for 10/476999 on October 31, 2005, AstraZeneca Ref. 100553 | <input type="checkbox"/> |
| 30 | Copy of Advisory Action issued for 10/275824 on May 22, 2007, AstraZeneca Ref. 100046 | <input type="checkbox"/> |
| 31 | Copy of final OA issued for 10/275824 on February 8, 2007, AstraZeneca Ref. 100046 | <input type="checkbox"/> |
| 32 | Copy of non-final OA issued for 10/275824 on June 19, 2006, AstraZeneca Ref. 100046 | <input type="checkbox"/> |
| 33 | Copy of Advisory Action issued for 10/275824 on March 15, 2006, AstraZeneca Ref. 100046 | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|---------------|------------|
| Application Number | | 10575592 |
| Filing Date | | 2006-04-12 |
| First Named Inventor | Kettle | |
| Art Unit | 1624 | |
| Examiner Name | Mark L. Berch | |
| Attorney Docket Number | 101250-1P US | |

| | | |
|----|--|--------------------------|
| 34 | Copy of final OA issued for 10/275824 on November 30, 2005, AstraZeneca Ref. 100046 | <input type="checkbox"/> |
| 35 | Copy of non-final OA issued for 10/275824 on June 17, 2005, AstraZeneca Ref. 100046 | <input type="checkbox"/> |
| 36 | U.S. Application Serial No. 11/577833, Attorney Docket No. 101584-1P US, filed on April 24, 2007 | <input type="checkbox"/> |
| 37 | U.S. Application Serial No. 11/720913, Attorney Docket No. 101621-1P US, filed on June 5, 2007 | <input type="checkbox"/> |
| 38 | U.S. Application Serial No. 11/756967, Attorney Docket No. 102288-2 US, filed on June 1, 2007 | <input type="checkbox"/> |

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.